Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Market Intelligence

Set Alert for Market Intelligence

Mehta Analysis: Biopharma's 10% Myth

Viren Mehta, founder of Mehta Partners, LLC, considers the oft-repeated statement that the cost of drugs represents only 10% of US healthcare expenditure. Does it matter that the figure excludes a large and growing segment of medicine spending?

United States Pricing Debate Government Payers
Advertisement

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Scrip Asks… Is The Biosimilar Cost-Saving Theory Sustainable?

Scrip asks industry whether the promise of biosimilars producing substantial cost-savings is a sustainable model to help healthcare systems afford the next wave of expensive biologics. Drug developers and trade associations comment on the caveats still in play when it comes to biosimilars, cost-cutting and market access.

Biosimilars Market Access

The Pharma Pipeline Report Card 2017, An Infographic

The Pharmaceutical and Biotech industries’ R&D performance can be measured in a number of ways. Here is a look at its worldwide output of novel drug launches for 2016 and total pipeline size in 2017.

Research & Development Market Intelligence

Novartis's Entresto Voyage: Hindsight Is 20/20

What caused Novartis's innovative heart failure drug to falter, missing sales targets by $30m in 2016, and how is it expected to bounce back in 2017? Scrip explores Entresto's journey and what this experience shows about the changing face of pharma's customers.

Cardiovascular Market Access

Entresto Facing Pressure From Diabetes Drugs

With diabetes therapeutics adding cardiovascular risk reduction claims, Novartis's heart failure drug Entresto could face pressure from new fronts – just as sales start to take off.

Cardiovascular Metabolic Disorders

Real World Evidence Is Critical To Pharma’s Future: Can We Agree On What It Is?

Urgent calls for industry to generate and apply real world evidence were matched at a recent conference only by complaints about challenges faced by this growing, ill-defined evidence category.

Research and Development Strategies Clinical Trials

Lilly Breathing Down Amgen/Novartis's Necks With Three Phase III Migraine Wins

Lilly will seek FDA approval in the second half of 2017 for CGRP inhibitor galcanezumab based on three positive Phase III studies – within months of a filing for Amgen's and Novartis's CGRP inhibitor erenumab.

Clinical Trials Research and Development Strategies
See All
UsernamePublicRestriction

Register